← Back to Search

Cytokine

IFN-γ (interferon gamma-1b) injection for Myeloid Leukemia

Phase < 1
Waitlist Available
Led By Sawa Ito, MD; PhD
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Study Summary

This trial will test if IFN-γ can help people with AML/MDS that has relapsed after alloSCT by promoting graft-vs-leukemia (GVL).

Eligible Conditions
  • Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Stem Cell Transplant

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse events related to IFN-γ
Generation of phosphorylated-STAT1
Upregulation HLA l (HLA-ABC)
+2 more
Secondary outcome measures
Incidence of GVHD
Incidence of de novo GVHD
Malignant Blast Burden

Trial Design

1Treatment groups
Experimental Treatment
Group I: IFN-γExperimental Treatment1 Intervention
100mcg IFN-γ subcutaneously three times per week (Weeks 0-7), once per week (Weeks 8-12) (or per protocol guidance based on tolerability, response, or DLI infusions)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IFN-γ (interferon gamma-1b) injection
2021
Completed Early Phase 1
~10

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,719 Previous Clinical Trials
16,342,333 Total Patients Enrolled
Sawa Ito, MDLead Sponsor
Horizon Pharma USA, Inc.Industry Sponsor
22 Previous Clinical Trials
2,028 Total Patients Enrolled

Media Library

IFN-γ (Cytokine) Clinical Trial Eligibility Overview. Trial Name: NCT04628338 — Phase < 1
Myeloid Leukemia Research Study Groups: IFN-γ
Myeloid Leukemia Clinical Trial 2023: IFN-γ Highlights & Side Effects. Trial Name: NCT04628338 — Phase < 1
IFN-γ (Cytokine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04628338 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
Sawa Ito, MD 2021. "IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04628338.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top